Gregory Fraser
Stock Analyst at Truist Securities
(3.35)
# 1,007
Out of 4,761 analysts
34
Total ratings
53.85%
Success rate
16.82%
Average return
Main Sectors:
Stocks Rated by Gregory Fraser
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANIP ANI Pharmaceuticals | Maintains: Hold | $60 → $62 | $57.94 | +7.01% | 8 | Oct 22, 2024 | |
| BHC Bausch Health Companies | Maintains: Hold | $8 → $7 | $7.31 | -4.24% | 2 | Jul 25, 2024 | |
| XAIR Beyond Air | Maintains: Buy | $10 → $8 | $0.35 | +2,183.76% | 6 | Apr 30, 2024 | |
| BTMD biote | Maintains: Buy | $10 → $9 | $4.49 | +100.45% | 2 | Jan 18, 2024 | |
| AMRX Amneal Pharmaceuticals | Maintains: Buy | $6 → $7 | $7.83 | -10.60% | 4 | Nov 8, 2023 | |
| CORT Corcept Therapeutics | Maintains: Hold | $26 → $29 | $63.54 | -54.36% | 5 | Aug 3, 2023 | |
| NVCR NovoCure | Reiterates: Buy | $95 | $22.09 | +330.06% | 3 | Jun 6, 2023 | |
| EOLS Evolus | Maintains: Buy | $14 → $18 | $13.99 | +28.66% | 2 | May 26, 2023 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $45 → $40 | $13.02 | +207.22% | 2 | May 26, 2023 |
ANI Pharmaceuticals
Oct 22, 2024
Maintains: Hold
Price Target: $60 → $62
Current: $57.94
Upside: +7.01%
Bausch Health Companies
Jul 25, 2024
Maintains: Hold
Price Target: $8 → $7
Current: $7.31
Upside: -4.24%
Beyond Air
Apr 30, 2024
Maintains: Buy
Price Target: $10 → $8
Current: $0.35
Upside: +2,183.76%
biote
Jan 18, 2024
Maintains: Buy
Price Target: $10 → $9
Current: $4.49
Upside: +100.45%
Amneal Pharmaceuticals
Nov 8, 2023
Maintains: Buy
Price Target: $6 → $7
Current: $7.83
Upside: -10.60%
Corcept Therapeutics
Aug 3, 2023
Maintains: Hold
Price Target: $26 → $29
Current: $63.54
Upside: -54.36%
NovoCure
Jun 6, 2023
Reiterates: Buy
Price Target: $95
Current: $22.09
Upside: +330.06%
Evolus
May 26, 2023
Maintains: Buy
Price Target: $14 → $18
Current: $13.99
Upside: +28.66%
Arcutis Biotherapeutics
May 26, 2023
Maintains: Buy
Price Target: $45 → $40
Current: $13.02
Upside: +207.22%